Year Book of Psychiatry and Applied Mental Health 2013

1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Chapter 1. Child and Adolescent Psychiatry - p. 11 5. 1.1. Assessment and Diagnosis - p. 12 6. A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder - p. 13 7. A Multisite Study of the Clinical Diagnosis of Different Autism Spectrum Disorders - p. 14 8. Attachment in adolescence: overlap with parenting and unique prediction of behavioural adjustment - p. 15 9. DSM-5 Further Inflates Attention Deficit Hyperactivity Disorder - p. 16 10. Out of the Funhouse Mirrors: Steps Toward Understanding the Role of Parenting in Maladaptive Child Development - p. 17 11. Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in the National Comorbidity Survey Replication Adolescent Supplement - p. 18 12. Progressive Brain Changes in Children and Adolescents With First-Episode Psychosis - p. 19 13. Stimulant Medication Use in Children: A 12-Year Perspective - p. 20 14. Use and Abuse of Alcohol and Illicit Drugs in US Adolescents: Results of the National Comorbidity Survey–Adolescent Supplement - p. 21 15. Variability Among Research Diagnostic Interview Instruments in the Application of DSM-IV-TR Criteria for Pediatric Bipolar Disorder - p. 22 16. 1.2. Intervention Studies - p. 23 17. A Randomized Controlled Trial of Multisystemic Therapy and a Statutory Therapeutic Intervention for Young Offenders - p. 24 18. Cognitive Behavior Therapy Augmentation of Pharmacotherapy in Pediatric Obsessive-Compulsive Disorder: The Pediatric OCD Treatment Study II (POTS II) Randomized Controlled Trial - p. 25 19. Effects of Risperidone and Parent Training on Adaptive Functioning in Children with Pervasive Developmental Disorders and Serious Behavioral Problems - p. 26 20. EVENDOL, a new behavioral pain scale for children ages 0 to 7 years in the emergency department: Design and validation - p. 27 21. Risperidone and Divalproex Differentially Engage the Fronto-Striato- Temporal Circuitry in Pediatric Mania: A Pharmacological Functional Magnetic Resonance Imaging Study - p. 28 22. Suicidal Thoughts and Behavior With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine - p. 29 23. 1.3. Miscellaneous - p. 30 24. Multicenter Study of Brain Volume Abnormalities in Children and Adolescent-Onset Psychosis - p. 31 25. Neurocognitive Outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study - p. 32 26. Predictors of Initiation of Hookah Tobacco Smoking: A One-Year Prospective Study of First-Year College Women - p. 33 27. 1.4. Risk and Etiologic Factors - p. 34 28. Adolescent Irritability: Phenotypic Associations and Genetic Links With Depressed Mood - p. 35 29. An fMRI Study of Self-Regulatory Control and Conflict Resolution in Adolescents With Bulimia Nervosa - p. 36 30. Childhood maltreatment and DSM-IV adult mental disorders: comparison of prospective and retrospective findings - p. 37 31. Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis - p. 38 32. Differential Patterns of Abnormal Activity and Connectivity in the Amygdala–Prefrontal Circuitry in Bipolar-I and Bipolar-NOS Youth - p. 39 33. Early Risk Factors for Hyperactivity-Impulsivity and Inattention Trajectories From Age 17 Months to 8 Years - p. 40 34. Evidence That Autistic Traits Show the Same Etiology in the General Population and at the Quantitative Extremes (5%, 2.5%, and 1%) - p. 41 35. Excessive cannabis use is associated with earlier age at onset in bipolar disorder - p. 42 36. Gray Matter Volume Abnormalities in ADHD: Voxel-Based Meta-Analysis Exploring the Effects of Age and Stimulant Medication - p. 43 37. Investigating the Contribution of Common Genetic Variants to the Risk and Pathogenesis of ADHD - p. 44 38. Longitudinal Associations Among Youth Depressive Symptoms, Peer Victimization, and Low Peer Acceptance: An Interpersonal Process Perspective - p. 45 39. Migration From Mexico to the United States and Conduct Disorder: A Cross-National Study - p. 46 40. Parental Socioeconomic Status and Risk of Offspring Autism Spectrum Disorders in a Swedish Population-Based Study - p. 47 41. Physical Activity and Psychiatric Problems in Children - p. 48 42. Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students - p. 49 43. Risk Taking and the Adolescent Reward System: A Potential Common Link to Substance Abuse - p. 50 44. Spinning Our Wheels: Improving Our Ability to Respond to Bullying and Cyberbullying - p. 51 45. Temperament and Family Environment in the Development of Anxiety Disorder: Two-Year Follow-Up - p. 52 46. The Interaction of Parental History of Suicidal Behavior and Exposure to Adoptive Parents’ Psychiatric Disorders on Adoptee Suicide Attempt Hospitalizations - p. 53 47. The Moderating Role of Working Memory Capacity and Alcohol-Specific Rule-Setting on the Relation Between Approach Tendencies and Alcohol Use in Young Adolescents - p. 54 48. The ‘Twinkie Defense’: the relationship between carbonated non-diet soft drinks and violence perpetration among Boston high school students - p. 55 49. 1.5. Services and Outcomes - p. 56 50. Childhood Trajectories of Inattention and Hyperactivity and Prediction of Educational Attainment in Early Adulthood: A 16-Year Longitudinal Population-Based Study - p. 57 51. Foster Children: HHS Guidance Could Help States Improve Oversight of Psychotropic Prescriptions - p. 58 52. Racial/Ethnic Differences in Treatment for Substance Use Disorders Among U.S. Adolescents - p. 59 53. Technical Report—Pediatric and Adolescent Mental Health Emergencies in the Emergency Medical Services System - p. 60 54. Testing Standard and Modular Designs for Psychotherapy Treating Depression, Anxiety, and Conduct Problems in Youth: A Randomized Effectiveness Trial - p. 61 55. Treatment-Resistant Depressed Youth Show a Higher Response Rate if Treatment Ends During Summer School Break - p. 62 56. 1.6. Treatment Studies: Pharmacotherapy - p. 63 57. A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children With Autism - p. 64 58. A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents - p. 65 59. ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults - p. 66 60. Age-Grouped Differences in Adverse Drug Events from Psychotropic Medication - p. 67 61. Antidepressants and Psychostimulants in Pediatric Populations: Is there an Association with Mania? - p. 68 62. Blood Pressure and Heart Rate over 10 Years in the Multimodal Treatment Study of Children With ADHD - p. 69 63. Brain Activity in Adolescent Major Depressive Disorder Before and After Fluoxetine Treatment - p. 70 64. Pubertal delay in male nonhuman primates (Macaca mulatta) treated with methylphenidate - p. 71 65. Stimulants and Cardiovascular Events in Youth With Attention-Deficit/Hyperactivity Disorder - p. 72 66. Chapter 2. Psychotherapy - p. 73 67. 2.1. Mediators of Psychotherapy Outcome - p. 74 68. Do Treatment Manuals Undermine Youth–Therapist Alliance in Community Clinical Practice? - p. 75 69. Matching the Patient to the Therapist: The Roles of the Attachment Status and the Helping Alliance - p. 76 70. 2.2. Outcome Studies - p. 77 71. “El Grupo”: Bringing Psychotherapy to an Underserved Population - p. 78 72. A Body Image and Disordered Eating Intervention for Women in Midlife: A Randomized Controlled Trial - p. 79 73. A Controlled Comparison of the Effectiveness and Efficiency of Two Psychological Therapies for Posttraumatic Stress Disorder: Eye Movement Desensitization and Reprocessing vs. Emotional Freedom Techniques - p. 80 74. A Randomized Controlled Trial of Intensive Sleep Retraining (ISR): A Brief Conditioning Treatment for Chronic Insomnia - p. 81 75. A Randomized Controlled Trial of Online Versus Clinic-Based CBT for Adolescent Anxiety - p. 82 76. Adverse Effects of Cognitive Behavioral Therapy and Cognitive Remediation in Schizophrenia: Results of the Treatment of Negative Symptoms Study - p. 83 77. An Automated Internet Application to Help Patients With Bipolar Disorder Track Social Rhythm Stabilization - p. 84 78. Attachment and callous-unemotional traits in children with early-onset conduct problems - p. 85 79. Bereavement-Related Depressive Episodes: Characteristics, 3-Year Course, and Implications for the DSM-5 - p. 86 80. Brief Behavioral Activation and Problem-Solving Therapy for Depressed Breast Cancer Patients: Randomized Trial - p. 87 81. Brief eclectic psychotherapy v. eye movement desensitisation and reprocessing therapy for post-traumatic stress disorder: randomised controlled trial - p. 88 82. Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: randomised controlled trial - p. 89 83. Brief Strategic Family Therapy Versus Treatment as Usual: Results of a Multisite Randomized Trial for Substance Using Adolescents - p. 90 84. Change in Defense Mechanisms During Short-Term Dynamic and cognitive Therapy in Patients With Cluster C Personality Disorders - p. 91 85. Cognitive Behavioral Treatment of PTSD in Residents of Battered Women's Shelters: Results of a Randomized Clinical Trial - p. 92 86. Cognitive-Behavioral Treatment of Body Image Disturbance in a Congenitally Blind Patient with Anorexia Nervosa - p. 93 87. Cross-cultural psychotherapy. M. M. Bishop and G. Winokur (1956). Reprinted from the J Nerv Ment Dis. 123:369-375 - p. 94 88. d-Cycloserine Augmentation of Behavioral Therapy for the Treatment of Anxiety Disorders: A Meta-Analysis - p. 95 89. Group psychological therapies for depression in the community: systematic review and meta-analysis - p. 96 90. Interpersonal Psychotherapy (IPT) for PTSD: A Case Study - p. 97 91. Predicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk - p. 98 92. Problem-solving therapy for people who present to hospital with self-harm: Zelen randomised controlled trial - p. 99 93. Therapists’ professional and personal characteristics as predictors of outcome in short- and long-term psychotherapy - p. 100 94. 2.3. Psychotherapy without Psychotherapists - p. 101 95. Behavioural activation: history, evidence and promise - p. 102 96. Chapter 3. Alcohol and Substance Abuse - p. 103 97. 3.1. Addiction Treatmant - p. 104 98. Chronic Disease Management for Tobacco Dependence: A Randomized, Controlled Trial - p. 105 99. 3.2. Dual Diagnosis - p. 106 100. Alcohol Use Disorders in Schizophrenia: A National Cohort Study of 12,653 Patients - p. 107 101. Antidepressants for Major Depressive Disorder and Dysthymic Disorder in Patients With Comorbid Alcohol Use Disorders: A Meta-Analysis of Placebo-Controlled Randomized Trials - p. 108 102. Axis IV Psychosocial Problems among Patients with Psychotic or Mood Disorders with a Cannabis Use Disorder Comorbidity - p. 109 103. Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California - p. 110 104. 3.3. Genetics and Progression - p. 111 105. Abnormal Brain Structure Implicated in Stimulant Drug Addiction - p. 112 106. Effects of the Circadian Rhythm Gene Period 1 (Per1) on Psychosocial Stress-Induced Alcohol Drinking - p. 113 107. Prediction of the Risk of Comorbid Alcoholism in Schizophrenia by Interaction of Common Genetic Variants in the Corticotropin-Releasing Factor System - p. 114 108. 3.4. Miscellaneous - p. 115 109. Extent of illicit drug use and dependence, and their contribution to the global burden of disease - p. 116 110. Use and Abuse of Alcohol and Illicit Drugs in US Adolescents: Results of the National Comorbidity Survey–Adolescent Supplement - p. 117 111. 3.5. Neuroscience Advances - p. 118 112. Effects of Adrenal Sensitivity, Stress- and Cue-Induced Craving, and Anxiety on Subsequent Alcohol Relapse and Treatment Outcomes - p. 119 113. Effects of lowered serotonin transmission on cocaine-induced striatal dopamine response: PET [11C]raclopride study in humans - p. 120 114. Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-Methylenedioxymethamphetamine Polydrug Users - p. 121 115. Neuroscience: Behavioural effects of cocaine reversed - p. 122 116. 3.6. Pharmacologic Treatment - p. 123 117. A Randomized Trial of Nicotine-Replacement Therapy Patches in Pregnancy - p. 124 118. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence: A 2-Phase Randomized Controlled Trial - p. 125 119. Committee Opinion no. 524: Opioid Abuse, Dependence, and Addiction in Pregnancy - p. 126 120. Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial - p. 127 121. 3.7. Risk Factors - p. 128 122. A Family Intervention to Reduce Sexual Risk Behavior, Substance Use, and Delinquency Among Newly Homeless Youth - p. 129 123. Binge Drinking and Axis I Psychiatric Disorders in Community-Dwelling Middle-Aged and Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) - p. 130 124. Chronic Pain and Marijuana Use among a Nationally Representative Sample of Adults - p. 131 125. Early Start: A Cost–Beneficial Perinatal Substance Abuse Program - p. 132 126. Chapter 4. Psychiatry and the Law - p. 133 127. 4.1. Assessment and Treatment - p. 134 128. A Multivariate Twin Study of the DSM-IV Criteria for Antisocial Personality Disorder - p. 135 129. Perceptions of aggressive conflicts and others’ distress in children with callous-unemotional traits: ‘I’ll show you who’s boss, even if you suffer and I get in trouble’ - p. 136 130. Secondary Traumatic Stress in Attorneys and Their Administrative Support Staff Working With Trauma-exposed Clients - p. 137 131. 4.2. Domestic Violence - p. 138 132. Committee Opinion No. 518: Intimate Partner Violence - p. 139 133. Community-Level and Individual-Level Influences of Intimate Partner Violence on Birth Spacing in Sub-Saharan Africa - p. 140 134. 4.3. Euthanasia - p. 141 135. Legalise assisted suicide, UK Commission urges - p. 142 136. 4.4. Legal Issues - p. 143 137. Association of COL25A1 with Comorbid Antisocial Personality Disorder and Substance Dependence - p. 144 138. Association of Involuntary Psychiatric Examination with Probability of Arrest of People with Serious Mental Illness - p. 145 139. Collateral consequences of an ever-expanding prison system - p. 146 140. How Often Are Teens Arrested for Sexting? Data From a National Sample of Police Cases - p. 147 141. Legal Challenges for Substance Abuse Treatment During Disasters - p. 148 142. 4.5. Miscellaneous - p. 149 143. A data-driven war on crime - p. 150 144. 4.6. Violence - p. 151 145. A Second’s Chance: Gang Violence Task Force Prevention Program - p. 152 146. Addressing Intimate Partner Violence in Lesbian, Gay, Bisexual, and Transgender Patients - p. 153 147. Arrest Outcomes Associated With Outpatient Commitment in New York State - p. 154 148. Disentangling Structural Brain Alterations Associated With Violent Behavior From Those Associated With Substance Use Disorders - p. 155 149. Emergency department security programs, community crime, and employee assaults - p. 156 150. Homicide and Suicide During the Perinatal Period: Findings From the National Violent Death Reporting System - p. 157 151. Judicial Outcomes of Child Abuse Homicide - p. 158 152. The Relation of Serotonin-Related Gene and COMT Gene Polymorphisms With Criminal Behavior in Schizophrenic Disorder - p. 159 153. Chapter 5: Hospital and Community Psychiatry - p. 160 154. 5.1. Barriers to Care - p. 161 155. Importance of Anonymity to Encourage Honest Reporting in Mental Health Screening After Combat Deployment - p. 162 156. Association of Perceived Barriers With Prospective Use of VA Mental Health Care Among Iraq and Afghanistan Veterans - p. 163 157. Reported Mental Health Specialty Care in the 2010 HealthStyles Survey - p. 164 158. Incarceration Among Adults Who Are in the Public Mental Health System: Rates, Risk Factors, and Short-Term Outcomes - p. 165 159. Lost in the Crowd: Prison Mental Health Care, Overcrowding, and the Courts - p. 166 160. 5.2. Community Care - p. 167 161. Has the closure of psychiatric beds gone too far? Yes - p. 168 162. Outcomes From Consumer-Operated and Community Mental Health Services: A Randomized Controlled Trial - p. 169 163. A Comparison of Phone-Based and On-Site Assessment of Fidelity for Assertive Community Treatment in Indiana - p. 170 164. Views of Young People in Early Intervention Services for First-Episode Psychosis in England - p. 171 165. Do Empathy and Psychological Mindedness Affect Police Officers' Decision to Enter Crisis Intervention Team Training? - p. 172 166. Transitions Between Jail and Community-Based Treatment for Individuals With Co-Occurring Disorders - p. 173 167. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders - p. 174 168. Randomized Trial of Critical Time Intervention to Prevent Homelessness After Hospital Discharge - p. 175 169. Partners in Recovery: Social Support and Accountability in a Consumer-Run Mental Health Center - p. 176 170. Colocated General Medical Care and Preventable Hospital Admissions for Veterans With Serious Mental Illness - p. 177 171. 5.3. Depression - p. 178 172. Acceptance and commitment therapy as guided self-help for psychological distress and positive mental health: a randomized controlled trial - p. 179 173. 5.4. Economic Issues - p. 180 174. Uninsurance Among Nonelderly Adults With and Without Frequent Mental and Physical Distress in the United States - p. 181 175. Medicaid Cutbacks and State Psychiatric Hospitalization of Patients With Schizophrenia - p. 182 176. Study Finding Psych Follow-Up Faults Stirs Debate: Annals Letter Highlights “Phantom Panel” Problem - p. 183 177. Outcomes of 98,609 U.S. Department of Veterans Affairs Patients Enrolled in Telemental Health Services, 2006–2010 - p. 184 178. The Effect of Comprehensive Behavioral Health Parity on Choice of Provider - p. 185 179. An Examination of Costs, Charges, and Payments for Inpatient Psychiatric Treatment in Community Hospitals - p. 186 180. Economic Approaches to Improving Access to Evidence-Based and Recovery-Oriented Services for People With Severe Mental Illness - p. 187 181. 5.5. Epidemiology, Diagnosis, and Trends - p. 188 182. The population impact of improvements in mental health services: the case of Australia - p. 189 183. Absolute Risk of Suicide After First Hospital Contact in Mental Disorder - p. 190 184. Child Marriage in the United States and Its Association With Mental Health in Women - p. 191 185. 5.6. Hospital Care - p. 192 186. Coercion in Psychiatric Care: Systematic Review of Correlates and Themes - p. 193 187. Characteristics of Psychiatric Inpatients Who Experienced Restraint and Those Who Did Not: A Case-Control Study - p. 194 188. Aggression and seclusion on acute psychiatric wards: effect of short-term risk assessment - p. 195 189. Impact of Capacity Reductions in Acute Public-Sector Inpatient Psychiatric Services - p. 196 190. 5.7. Miscellaneous - p. 197 191. Predictors of cosmetic surgery and its effects on psychological factors and mental health: a population-based follow-up study among Norwegian females - p. 198 192. Stress and Mental Health Among Midlife and Older Gay-Identified Men - p. 199 193. Lessons Learned from Mental Health Enhancement and Suicide Prevention Activities in the Veterans Health Administration - p. 200 194. At Issue: Cochrane, Early Intervention, and Mental Health Reform: Analysis, Paralysis, or Evidence-Informed Progress? - p. 201 195. What Does Recovery Mean in Practice? A Qualitative Analysis of International Recovery-Oriented Practice Guidance - p. 202 196. Influence of Health Beliefs and Stigma on Choosing Internet Support Groups Over Formal Mental Health Services - p. 203 197. Treating Patients Who Strain the Research Psychotherapy Paradigm - p. 204 198. The effects of progress monitoring on subsequent readmission to psychiatric care: A six-month follow-up - p. 205 199. Usefulness of Symptom Feedback to Providers in an Integrated Primary Care–Mental Health Care Clinic - p. 206 200. Parent Medication Concerns Predict Underutilization of Mental Health Services for Minority Children With ADHD - p. 207 201. Comparison of the Mental Health of Female Adult Film Performers and Other Young Women in California - p. 208 202. Measurement-Based Care in Psychiatric Practice: A Policy Framework for Implementation - p. 209 203. 5.8. Post-Traumatic Stress Disorder (PTSD) and Stress - p. 210 204. Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial - p. 211 205. Prescribing Trends in Veterans With Posttraumatic Stress Disorder - p. 212 206. Prolonged Exposure Therapy for Combat- and Terror-Related Posttraumatic Stress Disorder: A Randomized Control Comparison With Treatment as Usual - p. 213 207. Trajectories of trauma symptoms and resilience in deployed US military service members: prospective cohort study - p. 214 208. Are we winning the war against posttraumatic stress disorder? - p. 215 209. Effect of Dwell Time on the Mental Health of US Military Personnel With Multiple Combat Tours - p. 216 210. Prevalence of Delayed-Onset Posttraumatic Stress Disorder in Military Personnel: Is There Evidence for this Disorder?: Results of a Prospective UK Cohort Study - p. 217 211. Longitudinal study of resilience and mental health in marines leaving military service - p. 218 212. Development of Posttraumatic Stress Disorder After Mild Traumatic Brain Injury - p. 219 213. Mindfulness Is Associated With Fewer PTSD Symptoms, Depressive Symptoms, Physical Symptoms, and Alcohol Problems in Urban Firefighters - p. 220 214. Lessons Learned From the New York State Mental Health Response to the September 11, 2001, Attacks - p. 221 215. 5.9. Schizophrenia - p. 222 216. “How to Speak to Your Psychiatrist”: Shared Decision-Making Training for Inpatients With Schizophrenia - p. 223 217. Predicting Psychiatric Hospital Admission Among Adults With Schizophrenia - p. 224 218. Negative childhood experiences and mental health: theoretical, clinical and primary prevention implications - p. 225 219. The Role of Expressed Emotion in Relationships Between Psychiatric Staff and People With a Diagnosis of Psychosis: A Review of the Literature - p. 226 220. “How to Speak to Your Psychiatrist”: Shared Decision-Making Training for Inpatients With Schizophrenia - p. 227 221. 5.10. Violence - p. 228 222. Protective Factors and Risk Modification of Violence in Iraq and Afghanistan War Veterans - p. 229 223. Dangerous and severe personality disorder - p. 230 224. Violence among female stalkers - p. 231 225. Chapter 6: Clinical Psychiatry - p. 232 226. 6.1. Anxiety - p. 233 227. Assessment and Medication Management of Paediatric Obsessive-Compulsive Disorder - p. 234 228. Attention Bias Modification Treatment for Pediatric Anxiety Disorders: A Randomized Controlled Trial - p. 235 229. Behavior as information: “If I avoid, then there must be a danger” - p. 236 230. Epidemiology of Fears and Specific Phobia in Adolescence: Results From the Mexican Adolescent Mental Health Survey - p. 237 231. Myocardial infarction and generalised anxiety disorder: 10-Year follow-up - p. 238 232. National Trends in the Antipsychotic Treatment of Psychiatric Outpatients With Anxiety Disorders - p. 239 233. Rage Attacks in Pediatric Obsessive-Compulsive Disorder: Phenomenology and Clinical Correlates - p. 240 234. Skin picking and trichotillomania in adults with obsessive-compulsive disorder - p. 241 235. Striatal Functional Alteration During Incentive Anticipation in Pediatric Anxiety Disorders - p. 242 236. 6.2. Bipolar Disorder - p. 243 237. A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar I disorder - p. 244 238. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder - p. 245 239. A Randomized Controlled Trial of Risperidone, Lithium, or Divalproex Sodium for Initial Treatment of Bipolar I Disorder, Manic or Mixed Phase, in Children and Adolescents - p. 246 240. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode - p. 247 241. A Randomized, Placebo-Controlled Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain - p. 248 242. An Automated Internet Application to Help Patients With Bipolar Disorder Track Social Rhythm Stabilization - p. 249 243. Antiepileptic Drugs for Bipolar Disorder and the Risk of Suicidal Behavior: A 30-Year Observational Study - p. 250 244. Aripiprazole in pediatric psychosis and bipolar disorder: A clinical review - p. 251 245. Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis - p. 252 246. Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder: Results of a 12-Week Core Study and 40-Week Extension - p. 253 247. Bipolar depression: Clinical correlates of receiving antidepressants - p. 254 248. Clinical Expression of Bipolar Disorder Type I as a Function of Age and Polarity at Onset: Convergent Findings in Samples From France and the United States - p. 255 249. Cognitive behaviour therapy and supportive therapy for bipolar disorders: relapse rates for treatment period and 2-year follow-up - p. 256 250. Creativity and mental disorder: family study of 300 000 people with severe mental disorder - p. 257 251. Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder - p. 258 252. Glutamatergic Effects of Divalproex in Adolescents With Mania: A Proton Magnetic Resonance Spectroscopy Study - p. 259 253. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial - p. 260 254. Omega-3 for Bipolar Disorder: Meta-Analyses of Use in Mania and Bipolar Depression - p. 261 255. The relationship between use of antidepressants and resource utilization among patients with manic or mixed bipolar disorder episodes: Findings from a managed care setting - p. 262 256. Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998–2009 - p. 263 257. 6.3. Depression - p. 264 258. A comorbid anxiety disorder does not result in an excess risk of death among patients with a depressive disorder - p. 265 259. A double blind randomized trial of unilateral left and bilateral prefrontal cortex transcranial magnetic stimulation in treatment resistant major depression - p. 266 260. A Positive 2-Item Patient Health Questionnaire Depression Screen Among Hospitalized Heart Failure Patients is Associated With Elevated 12-Month Mortality - p. 267 261. A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression - p. 268 262. A randomized trial comparing repetitive transcranial magnetic stimulation given 3 days/week and 5 days/week for the treatment of major depression: is efficacy related to the duration of treatment or the number of treatments? - p. 269 263. A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression - p. 270 264. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease - p. 271 265. A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder - p. 272 266. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression - p. 273 267. An increase in depressive symptoms after myocardial infarction predicts new cardiac events irrespective of depressive symptoms before myocardial infarction - p. 274 268. Are Antipsychotics or Antidepressants Needed for Psychotic Depression? A Systematic Review and Meta-Analysis of Trials Comparing Antidepressant or Antipsychotic Monotherapy With Combination Treatment - p. 275 269. Association of Coexisting Diabetes and Depression With Mortality After Myocardial Infarction - p. 276 270. Association of Depression With Increased Risk of Dementia in Patients With Type 2 Diabetes: The Diabetes and Aging Study - p. 277 271. Behavioural activation: history, evidence and promise - p. 278 272. Belief in the harmfulness of antidepressants: Associated factors and change over 16 years - p. 279 273. Can People With Nonsevere Major Depression Benefit From Antidepressant Medication? - p. 280 274. Clinical predictors of response and remission in inpatients with depressive syndromes - p. 281 275. Combination of Antidepressants in the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis - p. 282 276. Culture, bereavement, and psychiatry - p. 283 277. Delayed sleep phase syndrome is related to seasonal affective disorder - p. 284 278. Early Response and Remission as Predictors of a Good Outcome of a Major Depressive Episode at 12-Month Follow-Up: A Prospective, Longitudinal, Observational study - p. 285 279. Effects of cognitive therapy versus interpersonal psychotherapy in patients with major depressive disorder: a systematic review of randomized clinical trials with meta-analyses and trial sequential analyses - p. 286 280. Efficacy of Dose Increase Among Nonresponders to Low-Dose Aripiprazole Augmentation in Patients With Inadequate Response to Antidepressant Treatment: A Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial - p. 287 281. Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: systematic review - p. 288 282. Electroconvulsive therapy reduces frontal cortical connectivity in severe depressive disorder - p. 289 283. Long term follow up of suicide in a clinically depressed community sample - p. 290 284. Persistent Pulmonary Hypertension of the Newborn and Selective Serotonin Reuptake Inhibitors: Lessons From Clinical and Translational Studies - p. 291 285. Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D - p. 292 286. Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features - p. 293 287. Potential Utility of Optogenetics in the Study of Depression - p. 294 288. Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Unipolar and Bipolar Depression - p. 295 289. Targeting the Glutamatergic System to Treat Major Depressive Disorder: Rationale and Progress to Date - p. 296 290. The efficacy of mindfulness-based cognitive therapy in recurrent depressed patients with and without a current depressive episode: a randomized controlled trial - p. 297 291. The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder - p. 298 292. Treating Depression After Initial Treatment Failure: Directly Comparing Switch and Augmenting Strategies in STAR*D - p. 299 293. 6.4. General Psychiatry - p. 300 294. A longitudinal study of the bi-directional relationship between tobacco smoking and psychological distress in a community sample of young Australian women - p. 301 295. A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine - p. 302 296. A Naturalistic Study of Intramuscular Haloperidol Versus Intramuscular Olanzapine for the Management of Acute Agitation - p. 303 297. A Population Based Analysis of Subclinical Psychosis and Help-Seeking Behavior - p. 304 298. An Analysis of the Slowdown in Growth of Spending for Psychiatric Drugs, 1986–2008 - p. 305 299. Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine: A Randomized Controlled Open-Label Study - p. 306 300. Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: randomised controlled trial - p. 307 301. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial - p. 308 302. Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-Analysis - p. 309 303. Telephone versus face-to-face administration of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, for diagnosis of psychotic disorders - p. 310 304. The use of hormonal contraceptive agents and mood disorders in women - p. 311 305. Use of Obesity-Related Care by Psychiatric Patients - p. 312 306. 6.5. Miscellaneous - p. 313 307. A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders - p. 314 308. Adverse Effects of Second-Generation Antipsychotics in Children and Adolescents: A Bayesian Meta-Analysis - p. 315 309. Antipsychotics activate the TGFβ pathway effector SMAD3 - p. 316 310. Attainment and Stability of Sustained Symptomatic Remission and Recovery Among Patients With Borderline Personality Disorder and Axis II Comparison Subjects: A 16-Year Prospective Follow-Up Study - p. 317 311. Development of a Cosmetic Procedure Screening Questionnaire (COPS) for Body Dysmorphic Disorder - p. 318 312. Does the Presence of One Feature of Borderline Personality Disorder Have Clinical Significance? Implications for Dimensional Ratings of Personality Disorders - p. 319 313. Flourishing or floundering? Prevalence and correlates of anxiety and depression among a population-based sample of adult cancer survivors 6 months after diagnosis - p. 320 314. Longitudinal course of obsessive-compulsive disorder in patients with anxiety disorders: a 15-year prospective follow-up study - p. 321 315. Long-Term Follow-Up of Gut-Directed Hypnotherapy vs. Standard Care in Children With Functional Abdominal Pain or Irritable Bowel Syndrome - p. 322 316. 6.6. Psychitary in General Medicine - p. 323 317. Cefixime-Induced Oculogyric Crisis - p. 324 318. What’s It Worth? Public Willingness to Pay to Avoid Mental Illnesses Compared With General Medical Illnesses - p. 325 319. 6.7. Schizophrenia - p. 326 320. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia - p. 327 321. A Randomized Controlled Trial of the Illness Management and Recovery Program for Persons With Schizophrenia - p. 328 322. A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of High-Dose Quetiapine in Patients With Persistent Symptoms of Schizophrenia or Schizoaffective Disorder - p. 329 323. A Web-Based Program to Empower Patients Who Have Schizophrenia to Discuss Quality of Care With Mental Health Providers - p. 330 324. Adherence Patterns With First- Versus Second-Generation Antipsychotics for Newly Diagnosed Schizophrenia in Taiwan - p. 331 325. Adherence to Guidelines and Treatment Compliance in the Chilean National Program for First-Episode Schizophrenia - p. 332 326. Antibody-mediated encephalitis: a treatable cause of schizophrenia - p. 333 327. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis - p. 334 328. Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine: A Randomized Controlled Open-Label Study - p. 335 329. Assessment of Posttraumatic Symptoms in Patients With First-Episode Psychosis - p. 336 330. Augmenting Clozapine With Sertindole: A Double-Blind, Randomized, Placebo-Controlled Study - p. 337 331. Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-Year Population-Based Register Study - p. 338 332. Bupropion Sustained Release Added to Group Support for Smoking Cessation in Schizophrenia: A New Randomized Trial and a Meta-Analysis - p. 339 333. Cannabis, COMT and psychotic experiences - p. 340 334. Clinical, Functional, and Intertask Correlations of Measures Developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium - p. 341 335. Concordance between chart review and structured interview assessments of schizophrenic symptoms - p. 342 336. Cortical thickness, gray matter volume, and white matter anisotropy and diffusivity in schizophrenia - p. 343 337. Cost-Effectiveness of 12-Month Therapeutic Assertive Community Treatment as Part of Integrated Care Versus Standard Care in Patients With Schizophrenia Treated With Quetiapine Immediate Release (ACCESS Trial) - p. 344 338. Early Intervention for Psychosis - p. 345 339. Effects of Moderate-Dose Treatment With Varenicline on Neurobiological and Cognitive Biomarkers in Smokers and Nonsmokers With Schizophrenia or Schizoaffective Disorder - p. 346 340. Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial - p. 347 341. Eicosapentaenoic Acid Interventions in Schizophrenia: Meta-Analysis of Randomized, Placebo-Controlled Studies - p. 348 342. Executive Function Predicts Response to Antiaggression Treatment in Schizophrenia: A Randomized Controlled Trial - p. 349 343. Extended-Release Intramuscular Paliperidone Palmitate: A Review of its Use in the Treatment of Schizophrenia - p. 350 344. Functional magnetic resonance imaging correlates of memory encoding in relation to achieving remission in first-episode schizophrenia - p. 351 345. Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia - p. 352 346. Increased Stress-Induced Dopamine Release in Psychosis - p. 353 347. Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study - p. 354 348. Is Traumatic Brain Injury A Risk Factor for Schizophrenia? A Meta-Analysis of Case-Controlled Population-Based Studies - p. 355 349. Predicting the development of schizophrenia in high-risk populations: systematic review of the predictive validity of prodromal criteria - p. 356 350. Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia - p. 357 351. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia - p. 358 352. Self-perceived cognitive functioning does not correlate with objective measures of cognition in schizophrenia - p. 359 353. Self-stigma and its relationship with insight, demoralization, and clinical outcome among people with schizophrenia spectrum disorders - p. 360 354. Sleep and circadian rhythm disruption in schizophrenia - p. 361 355. Sleep in schizophrenia: time for closer attention - p. 362 356. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment - p. 363 357. 6.8. Substance Abuse - p. 364 358. Are early-onset cannabis smokers at an increased risk of depression spells? - p. 365 359. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort - p. 366 360. Doctor and Pharmacy Shopping for Controlled Substances - p. 367 361. ‘Legal Highs’ – novel and emerging psychoactive drugs: a chemical overview for the toxicologist - p. 368 362. Prospective Assessment of Transient Cocaine-Induced Psychotic Symptoms in a Clinical Setting - p. 369 363. Serotonin Syndrome Associated With MDPV Use: A Case Report - p. 370 364. 6.9. Suicide - p. 371 365. Insight in schizophrenia and risk of suicide: a systematic update - p. 372 366. The association between anomalous self-experience and suicidality in first-episode schizophrenia seems mediated by depression - p. 373 367. Chapter 7: Biological Psychiatry - p. 374 368. 7.1. Schizophrenia - p. 375 369. Altered Cell Cycle Dynamics in Schizophrenia - p. 376 370. Aripiprazole and Dehydroaripiprazole Plasma Concentrations and Clinical Responses in Patients With Schizophrenia - p. 377 371. Bleuler and the Neurobiology of Schizophrenia - p. 378 372. Polymorphisms of INSIG2, MC4R, and LEP Are Associated With Obesity- and Metabolic-Related Traits in Schizophrenic Patients - p. 379